BackAdma Biologics Overview
Adma Biologics Inc

Adma Biologics Target Price

Where could ADMA trade next? Consensus target price: $20.

Get informed when a big investor buys or sells

+ Follow

Share Price

$9.78

Average Target Price

$20.20106.5% upside

5 analysts in the last 4 months

High: $24 | Low: $17

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-07-15Mizuho Securities$1773.8% upsideOpen
2026-06-10Raymond JamesRyan Deschner$21114.7% upsideOpen
2026-05-07Canaccord GenuityGary Nachman$1884% upsideOpen
2026-04-20Canaccord Genuity$21114.7% upsideOpen
2026-04-13Mizuho SecuritiesAnthony Petrone$24145.4% upsideOpen
2024-10-14H.C. WainwrightRaghuram Selvaraju$1884% upsideOpen
2024-06-20Mizuho SecuritiesAnthony Petrone$1443.1% upsideOpen
2023-01-03H.C. Wainwright$4.554% downsideOpen
2022-11-10Mizuho Securities$638.7% downsideOpen
2022-07-25H.C. Wainwright$459.1% downsideOpen

Adma Biologics (ADMA) FAQ

Adma Biologics's target price stands at $20. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

The Street's average target of $20 for ADMA implies 106.5% upside versus today's price ($9.78). Positive implied upside usually reflects optimism on growth or margins, while a large downside can signal valuation or fundamental concerns. Check recommendation mix and recent target changes for more context.

The history chart shows how Adma Biologics's target price evolved across reporting periods, while the comparison chart places ADMA next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, target price is commonly used to spot outliers. Adma Biologics's reading of $20 is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.